Immuneering to Unveil Cancer Drug Data at AACR 2026

Data From 64 Patients to Debut at AACR 2026

Immuneering Corporation (Nasdaq: IMRX) announced on March 17, 2026, that it will present key molecular data for its lead oncology drug, atebimetinib. The presentation will occur at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on April 20, 2026. The findings are based on an analysis of circulating tumor DNA (ctDNA) from a cohort of at least 64 patients with RAS-mutant solid tumors who were treated with the drug.

The poster presentation will specifically highlight that acquired alterations in the MAPK pathway, a common cause of treatment resistance, were rarely observed in patients. This preview of positive data sets the stage for a significant scientific reveal at one of the industry's major conferences, drawing investor attention to the drug's potential.

Atebimetinib Aims to Overcome Treatment Resistance

Atebimetinib is engineered as a novel Deep Cyclic Inhibitor of MEK, a component of the MAPK cellular pathway that drives tumor growth. While many inhibitors targeting this pathway exist, their effectiveness is often short-lived as tumors develop resistance. Immuneering designed atebimetinib to mitigate the selective pressure that causes these resistance mechanisms to emerge.

The forthcoming data aims to validate this approach, suggesting the drug could provide more durable anti-tumor activity and sustained clinical benefit for patients. By constraining the tumor's ability to adapt, atebimetinib could overcome the limitations of conventional MAPK inhibition and improve overall survival, a primary goal for the late-stage oncology company.

Pivotal Phase 3 Pancreatic Cancer Trial Set for Mid-2026

Underscoring its confidence in the drug, Immuneering is preparing to launch a globally randomized, pivotal Phase 3 trial named MAPKeeper 301. The study will evaluate atebimetinib combined with chemotherapy in first-line pancreatic cancer patients. The company expects to dose the first patient in the trial in mid-2026.

This advancement into a late-stage trial marks a critical milestone for the company and its shareholders. A successful Phase 3 outcome would provide a clear path toward regulatory approval and commercialization, positioning atebimetinib as a potential new standard of care for a cancer with significant unmet needs.